➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Mallinckrodt
McKinsey
Boehringer Ingelheim
Harvard Business School
Johnson and Johnson

Last Updated: June 12, 2021

DrugPatentWatch Database Preview

Patent: 10,703,800

« Back to Dashboard

Summary for Patent: 10,703,800
Title:Cell culture medium
Abstract: Provided herein, inter alia, are compositions and methods for culturing mammalian cells. In certain aspects, the composition is a medium containing one or more of a lithium ion source, one or more fatty acids, and/or ethanol. Use of any of the cell culture media described herein to culture cells that have been genetically engineered to produce one or more recombinant polypeptides (for example, antibodies) can result in increased titers, a more favorable glycosylation profile, and/or modulated (e.g. decreased) amounts of high and low molecular weight species, and/or modulated (e.g. decreased) amounts of acidic or basic charge variants, compared to cells cultured in a medium that does not contain one or more of a lithium ion source, one or more fatty acids, and/or ethanol.
Inventor(s): Leber; Christopher T. (San Diego, CA), Shen; Michael W.Y. (San Diego, CA), Tao; Yiwen (San Diego, CA), Murray, IV; Hugh Eugene (San Diego, CA)
Assignee: LA JOLLA BIOLOGICS, INC. (San Diego, CA)
Application Number:15/498,221
Patent Claims:see list of patent claims

Details for Patent 10,703,800

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Centocor Inc REOPRO abciximab INJECTABLE; INJECTION 103575 001 1994-12-22   Get Started Free LA JOLLA BIOLOGICS, INC. (San Diego, CA) 2036-04-26 RX search
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 001 1997-11-26   Get Started Free LA JOLLA BIOLOGICS, INC. (San Diego, CA) 2036-04-26 RX search
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 002 1997-11-26   Get Started Free LA JOLLA BIOLOGICS, INC. (San Diego, CA) 2036-04-26 RX search
Novartis SIMULECT basiliximab VIAL; SINGLE-USE 103764 001 1998-05-12   Get Started Free LA JOLLA BIOLOGICS, INC. (San Diego, CA) 2036-04-26 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Mallinckrodt
Dow
Boehringer Ingelheim
Colorcon
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.